According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
To interrogate whether liraglutide improved cell function, we assessed GSIS in vivo ( Figures 4F, G
The net result is lower blood pressure despite a harder-working heart
Ongoing use of weight management medications supports normalization of these hormones and aids long-term weight maintenance, Dawkins adds
The whitening injection price in Pakistan, especially in cities such as Lahore, Karachi, and Islamabad, can differ